Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q3 2024 · 10-Q
Revenue—
Net Income-$8.37K-$8.37KN/M vs Q3 2023 EPS Diluted$0.00$0.00no prior Q3 2023 on file Operating Income-$8,367N/M Operating Cash Flowderived$396,437+3,808.5%
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end